Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Chronic spontaneous urticaria
18 evidence topics · 13 sources
United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual standardized prevalence of diagnosed CSU among adults across three databases increased from 0.052% in 2012 to 0.191% in 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The standardized period prevalence of diagnosed CSU among pediatric patients ranged from 0.193% to 0.304% across the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“most of the patients (≥ 80%) were diagnosed with unspecified urticaria, followed by idiopathic urticaria and other urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: cumulative prevalence of diagnosed CSU of 0.57% in adults in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated cumulative prevalence of diagnosed CSU was 0.57% (women: 0.80%; men: 0.32%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition with substantial clinical burden that affects 0.23% to 0.78% of the US population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded
“This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults who self-reported receiving a diagnosis of CSU from a healthcare provider in the past 12 months were included in the analysis for all outcomes and for the calculation of the weighted 12-month prevalence of diagnosed CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%–0.78%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria prevalence of 0.23% in adults, cross-sectional electronic health records analysis
“To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of administrative data has the potential to underestimate burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
North America: chronic urticaria point prevalence of 0.1% in a global meta-analysis
“The objective of this study was to systematically evaluate and summarize the prevalence of chronic urticaria by evaluating population-based studies worldwide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We performed a systematic search in PUBMED and EMBASE for population-based studies of cross-sectional or cohort design and studies based on health insurance/system databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen studies were included in the systematic evaluation and 11 in the meta-analysis including data from over 86 000 000 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Asian studies combined showed a higher point prevalence of chronic urticaria (1.4%, 95%-CI 0.5-2.9) than those from Europe (0.5%, 0.2-1.0) and Northern American (0.1%, 0.1-0.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The four studies that examined time trends indicated an increasing prevalence of chronic urticaria over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria prevalence range and female to male ratio in the Joint Task Force practice parameter
United States: chronic urticaria prevalence in adults by sex, age, and race
“To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States by age: higher diagnosed CSU prevalence in pediatric than adult populations, Novartis-funded study
| Database and period | Adults (aged 18 years or older), prevalence (95% CI) | Pediatric patients (aged under 18 years), prevalence (95% CI) |
|---|---|---|
| Optum EHR, 2012 to 2018 | “0.120% (0.119–0.120)”View highlighted excerpt for this quote | “0.193% (0.191–0.195)”View highlighted excerpt for this quote |
| Optum CDM, 2012 to 2018 | “0.277% (0.275–0.279)”View highlighted excerpt for this quote | “0.304% (0.300–0.308)”View highlighted excerpt for this quote |
| MarketScan, 2012 to 2017 | “0.256% (0.248–0.265)”View highlighted excerpt for this quote | “0.264% (0.261–0.266)”View highlighted excerpt for this quote |
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of CSU in the present study was higher among pediatric patients than among adults across all databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: age at diagnosis and sex of adults with self-reported diagnosed CSU, Novartis-funded survey
“This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Female predominance from age 31 years in the international CURE registry
“We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statistically significant female predominance started at age 31 (<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU demonstrates a pronounced sex disparity, with females being disproportionately affected—evidenced by at least twofold higher incidences in females compared with males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Children: no sex difference in chronic urticaria prevalence under age 15 years
Children in five European countries: one-year diagnosed CSU prevalence of 0.75% from a physician survey
“A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Germany: lifetime and 12-month prevalence of chronic urticaria in a representative Berlin population survey
“A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime prevalence rate of urticaria was 8.8% (95% CI 7.9-9.7%) for all types of urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime prevalence for CU was 1.8% (95% CI 1.4-2.3%), and prevalence for the 12 months before assessment was 0.8% (95% CI 0.6-1.1%), and 70.3% were female.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: annual prevalence of CSU in a general practitioner database, 2002 to 2013
“The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence of CSU ranged from 0·02% in 2002 to 0·38% in 2013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For both prevalence and incidence rates, female patients outnumbered male.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: annual prevalence of CSU in primary care, 2002 to 2022
“A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual CSU prevalence ranged from 0.41% in 2002 to 0.35% in 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global: urticaria prevalence and female share in the Global Burden of Disease 2021 study
“Globally, the total number of urticaria cases increased from 47,949,600 (42,267,752 − 54,859,773) in 1990 to 66,483,473 (59,240,738 − 74,912,351) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meanwhile, the prevalence rate decreased from 899.01 (792.48-1028.56) per 100,000 population in 1990 to 842.49 (750.70-949.30) per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2021, females accounted for 58.94% of the total urticaria cases, with a female/male ratio of 1.44.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: lifetime prevalence of urticaria
“The lifetime prevalence of acute urticaria is estimated to be approximately 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urticaria is a frequent disease affecting up to 20% of the world population at some point during their lifetime, with over half of those patients reporting angioedema, and the global prevalence continues to increase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote